Abstract
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet, 401(10391):1853-1865, 16 Apr 2023
Cited by: 99 articles | PMID: 37075781
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Target Oncol, 19(3):359-370, 01 May 2024
Cited by: 0 articles | PMID: 38691295
Durvalumab: A Review in Advanced Biliary Tract Cancer.
Target Oncol, 18(6):965-972, 09 Nov 2023
Cited by: 1 article | PMID: 37943483 | PMCID: PMC10667376
Review Free full text in Europe PMC
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Oncologist, 26(5):433-438, 25 Mar 2021
Cited by: 52 articles | PMID: 33687763 | PMCID: PMC8100557
Review Free full text in Europe PMC
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist, 24(4):563-569, 12 Dec 2018
Cited by: 82 articles | PMID: 30541754 | PMCID: PMC6459239
Funding
Funders who supported this work.